Atropos Health, Kythera Labs Team Up for Oncology Data Expansion

Atropos Health, a pioneering company in generating real-world evidence (RWE) from healthcare data, has announced a strategic partnership with Kythera Labs, a leading healthcare data and technology firm. This collaboration marks a significant step in the expansion of the Atropos Evidence™ Network, the largest federated healthcare data network in the industry, and particularly bolsters its multimodal oncology capabilities. The Partnership and Key Developments The partnership began in Palo Alto, California, as both companies signed a multiyear agreement focused on transforming data and molecular biology insights into tangible health outcomes. This collaboration is expected to enhance the quality and scope of data available to researchers and healthcare providers, ultimately supporting more accurate and informed decision-making in oncology. Expansion of Datasets With the addition of Kythera Labs' high-quality datasets, the Atropos Evidence Network now offers a richer array of data for generating actionable insights. Kythera's datasets are renowned for their fidelity and comprehensiveness, covering the entire oncology care continuum. This includes detailed patient interactions, nuanced treatment decisions, and thorough provider engagements. These data points are derived from Kythera's Remastered Source Data, a unique collection that ensures accuracy and depth. Utilization of Advanced Scoring Tools Atropos Health leverages its Real World Data Score® (RWDS) and Real World Fitness Score® (RWFS) tools to evaluate and match these datasets to specific research questions. These tools help users identify the most suitable datasets, ensuring that the data is "fit-for-purpose" and enhancing the reliability of the insights generated. Dr. Brigham Hyde, CEO and co-founder of Atropos Health, emphasized that this expansion will significantly increase the network's ability to provide data that is precisely tailored to its members' needs. Enhanced Research and Clinical Decisions The integration of Kythera Labs' Oncology Event asset into the Atropos Evidence Network will facilitate quicker and more efficient research processes. Researchers and healthcare providers can access this comprehensive data to make better-informed decisions, expedite clinical research, and enhance the effectiveness of clinical trials. This is particularly crucial in oncology, where rapid advancements and personalized treatment plans can make a substantial difference in patient outcomes. Secure and Federated Data Model The Atropos Evidence Network operates on GENEVA OS™ (Generative Evidence Acceleration Operating System), a federated model that forms secure, cloud-based connections between data proprietors and clinical insight seekers. This model ensures that de-identified data remains within its original source while allowing network members to pose clinical questions. Within 48 hours, users receive a novel retrospective observational study in response, dramatically reducing the time and cost associated with traditional data acquisition and analysis methods. Mutual Benefits and Industry Impact For Kythera Labs, this partnership presents an opportunity to expand the reach and impact of its data. Jeff McDonald, CEO and co-founder of Kythera Labs, stated that the company is dedicated to bridging the gap between research and clinical care. He highlighted that collaborations like this one with Atropos Health are essential for advancing the field of oncology. Providing access to their enriched and analytics-ready data assets through the Atropos Evidence Network will help researchers and healthcare organizations reach conclusions faster and at a lower cost. Broader Applications and Future Prospects The multimodal nature of the expanded network means that it will not only serve oncology but also cater to other critical areas of healthcare. The enriched data and advanced scoring tools enable a wide range of applications, from optimizing patient care strategies to driving innovative medical research. By leveraging high-fidelity data and sophisticated analytics, the network aims to transform healthcare practices and outcomes across various specialties. About Atropos Health Atropos Health is the developer of GENEVA OS™, a system designed to rapidly generate healthcare evidence from a vast network of real-world data. The company works closely with healthcare and life science organizations to bridge evidence gaps, improve patient outcomes through data-driven care, and accelerate medical research. Their mission is to transform healthcare with timely and relevant real-world evidence. About Kythera Labs Kythera Labs specializes in unifying data science and data technology to achieve higher fidelity in healthcare data. The company's multi-source data captures over 310 million de-identified unique individuals, offering a robust platform for real-world data users to integrate, access, and analyze data efficiently. Their commitment to closing the gaps between R&D and clinical care aligns perfectly with Atropos Health's vision. Industry Insider Evaluation Industry experts have lauded this partnership for its potential to revolutionize oncology research and patient care. The combination of Atropos Health's advanced data analytics tools and Kythera Labs' rich, high-fidelity datasets is seen as a game-changer in the real-world evidence space. It addresses a critical need for timely, reliable, and comprehensive data, which is essential for making meaningful strides in cancer treatment and research. This collaboration not only enhances the capabilities of the Atropos Evidence Network but also sets a precedent for how federated data networks can effectively operate to benefit both data contributors and users. The transparency and analytical feedback provided to data contributors further reinforce the network's value proposition, ensuring continuous improvement and reliability of the data assets. In summary, the partnership between Atropos Health and Kythera Labs represents a significant advancement in the realm of healthcare data and technology. By combining their expertise and resources, they are poised to drive innovation and improve patient outcomes in oncology and beyond.